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LORNOXICAM 
Lornoxicam is a relatively new NSAID. It belongs to the 
oxicam group. Chemically it is a 4-hydroxycarboxamide 
[6-chloro-4-hydroxy-2-methyl-N-2-pyridyl-5H- thieno( 
2,3-e)-[1,2]-thiazine-2-carboxamide-1,1- dioxide]. 
PHARMACODYNAMIC PROPERTIES 
As with other nonsteroidal anti-inflammatory agents 
(NSAIDs), lornoxicam (chlortenoxicam) inhibits 
prostaglandin (PG) synthesis via inhibition of 
cyclooxygenase, but it does not inhibit 5-
lipoxygenas.lornoxicam inhibits polymorphonuclear 
(PMN)-leukocyte migration, inhibits the release of 
superoxide from human PMN-leukocytes, inhibits the 
release of platelet derived growth factor (PDGF) from 
human platelets and stimulates the synthesis of 
proteoglycans in cartilage in tissue culture.Lornoxicam 
was reported to be 100-fold more potent (on a molar basis) 
than tenoxicam in inhibiting PGD2 formation in rat 
polymorphonuclear leucocytes in vitro.1 
Besides its inhibitory effect on COX1 and COX-2 
peripheral receptors, is also increases endogenous 
dinorphin and beta-endorphin levels promoting central 
analgesic and anti-inflammatory effects. Its analgesic 
potency in animal pain models exceeds that of tenoxicam 
and piroxicam by approximately 12 and 13 fold 
respectively; whereas it is 4 to 6 fold more potent ad 
compared to indomethacin and diclofenac. Intravenous 
lonoxicam (8mg) has been shown to be as effective as 
morphine (20mg), pethidine (50mg) and tramadol (50mg) 
in the treatment of postoperative pain.2 
PHARMACOKINETIC PROPERTIES 
Lornoxicam is completely absorbed after oral 
administration, reaching peak plasma concentrations of 
280 mg/L within 2.5 hours after a 4 mg dose.3The area 
under the serum drug concentration-time curve (AUC) is 
proportional following lornoxicam doses between 2 to 6mg 
given twice daily for 2 weeks in healthy young volunteers. 
The Cmax and AUC of lornoxicam did indicate drug 
accumulation upon repeated administration.4 Intragastric 
food delays and reduces the absorption of lornoxicam as 
demonstrated by an approximate 15% decrease in AUC 
and an increase in tmax from 1.5 to 2.3 hours. After 
intramuscular injection maximum plasma concentrations 
are achieved after approximately 20-25 minutes. The 
absolute bioavailability after intramuscular injection is 97 
percent. It is found in the plasma in unchanged form and as 
its hydroxylated metabolite. The plasma protein binding of 
lornoxicam is 99 per cent. The apparent volume of 
distribution of lornoxicam is low (0.3L/Kg). Lornoxicam is 
extensively metabolished in liver by cytochrome 
P4502DC9 to inactive metabolite 5’-hydroxy-lornoxicam. 
Approximately 51 percent drug is excreted in faeces and 
42 percent via kidneys as inactive substance. The mean 
elimination half life is 3 to 4 hours.5 The drug has been 
found to be safe in elderly patients, patients with impaired 
renal function and patients with impaired hepatic 
functions.6,7  
INTERACTIONS  
Clonazepam and diazepam inhibit metabolism of 
lornoxicam. It does not interact with ranitidine and 
antacids. Concomitant administration of lornoxicam and 
anticoagulants or platelet aggregation inhibitors may 
prolong the bleeding time. It may increase the 
hypoglycemic effect of sulphonylureas and decrease the 
efficacy of diuretics and ACE inhibitors6. Lornoxicam did 
not alter phenazone (antipyrine) clearance in healthy 
volunteers, indicating a lack of effect on hepatic drug 
metabolising enzymes. 
ABSTRACT 
 Lornoxicam is a member of the oxicam group of nonsteroidal antiinflammatory drugs (NSAIDs), producing analgesic and 
antipyretic effects through the non-selective inhibition of cyclo-oxygenase-1 and -2. Besides its inhibitory effect on COX1 and 
COX-2 peripheral receptors, is also increases endogenous dinorphin and beta-endorphin levels promoting central analgesic 
and anti-inflammatory effects. Recently, lornoxicam has been introduced in Indian market in oral, intravenous and 
intramuscular formulations.  Lornoxicam is completely absorbed after oral administration, reaching peak plasma 
concentrations of 280 mg/L within 2.5 hours after a 4 mg dose.  After intramuscular injection maximum plasma 
concentrations are achieved after approximately 20-25 minutes. Lornoxicam is extensively metabolished in liver by 
cytochrome P4502DC9 to inactive metabolite 5’-hydroxy-lornoxicam. The mean elimination half life is 3 to 4 hours. There is 
plenty of literature available on the effect of lornoxicam on chronic and acute pain management. These preliminary finding 
require confirmation in further comparative studies.  
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DOSAGE AND ADMINISTRATION 
The most common dosages of lornoxicam used in 
clinical trials were 4 mg twice or 3 times daily or 8 mg 
twice daily (orally) for management of arthritic conditions, 
low back pain and ankylosing spondylitis, and single or 
repeated doses of 4 or 8 mg (orally or intravenously) for 
management of postoperative pain. 
Caution is recommended when using lornoxicam 
in patients with impaired renal function (although dosage 
adjustment does not appear to be necessary) and in those 
receiving warfarin, oral sulphonylureas, loop or thiazide 
diuretics, or digoxin. 
              Lornoxicam combines the high therapeutic 
potency of oxicams with an improved gastrointestinal 
toxicity profile. Quick-release formulation and injectable 
formulations of this drug are also available. It is also 
available in powder form as vial of 8mg both for 
intramuscular as well as intravenous use. The powder is to 
be dissolved in 2ml water for injection immediately prior 
to use. Lornoxicam must be administrated as an 
intramuscular injection in more than 5 seconds.  
THERAPEUTIC POTENTIAL IN CLINICAL 
STUDIES  
Lornoxicam has been shown to be effective and 
well tolerated in the treatment of chronic pain associated 
with a variety of conditions, including rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis, chronic low back 
pain and migraine prophylaxis. 
 Lornoxicam has been shown to be effective and well 
tolerated in the treatment of many acute painful conditions 
like acute sciatica/lumbosciatica, acute low back pain and 
acute post-operative pain following orthopaedic, 
gynaecological or other surgeries.Lornoxicam has been 
used in several trials for postoperative pain relief after 
various types of surgical procedures. 
            Norholt et al (1995) investigated the dose effect 
relationship of single doses of 4 to 32mg of lornoxicam 
and compared it with placebo as well as 10mg ketorolac in 
the treatment of pain after surgical removal of mandibular 
third molars in a double blind randomized study. A total of 
278 patients completed the study. The primary efficacy 
parameter was total pain relief after 6 hours. It was 
observed that lornoxicam 16 and 32 mg was significantly 
superior to lornoxicam 4mg. The effect of 10mg ketorolac 
seemed to be at the level of 8 to 16mg lornoxicam.8 
            Norholt et al (1996) in another study observed that 
effect of lornoxicam versus morphine in a double blind 
randomized trial for pain control after dental surgery. This 
trial compared the analgesic efficacy and tolerability of 
intramuscular injection of lornoxicam (4, 8, 16 and 20mg) 
with morphine (10 and 20mg) and placebo in 252 patients 
with moderate to severe pain following surgical removal of 
an impacted mandibular third molar. Patients treated with 
lornoxicam or morphine experienced a significantly 
greater pain relief over the 4 to 6 hour injection period than 
placebo recipients. This effect appeared to be dose 
dependent, with patients in the lornoxicam 4mg or 
morphine 10mg groups recording significantly lower pain 
relief scores than patients in the higher dosage groups of 
these drugs. No significant difference was detected 
between morphine 20mg group and lornoxicam 8, 16 and 
20mg groups. Lornoxicam was well tolerated at all doses 
and was associated with a significantly lower incidence of 
adverse effects than morphine 10 or 20mg. Thus, the 
analgesic efficacy of intramuscular lornoxicam at doses 
more than 4mg was superior to placebo and at doses more 
than 8mg was at least as effective as intramuscular 
morphine 20mg.9 
TuzunerOncul et al conducted astudy to compare 
the postoperative analgesic effects of preoperative 
intravenous paracetamol, diclofenac sodium and 
lornoxicam. In this study, sixty patients with impacted 
third molar who underwent surgical removal were 
randomly allocated into three groups: group P (n = 20), 
group D (n = 20) and group L (n = 20). Group P received 
preoperatively 1 g paracetamoli.v., group D 75 mg 
diclofenac sodium i.m. and group L 8 mg lornoxicam i.v. 
Postoperative pain intensity, additional consumption of 
analgesics postoperatively and postoperative complications 
were compared among groups.Maximum pain scores were 
recorded in postoperative 4th h in all groups (group L 22, 
14-44 mm; group P 24, 13-43 mm; group D 14, 10-24 mm, 
p = 0.117). Patients experienced high satisfaction scores 
which were comparable among groups (group L 85, 75-
100 mm; group P 87, 70-95 mm; group D 84, 77-98 mm, p 
= 0.457). This study concluded that preoperative 
intramuscular diclofenac, intravenous paracetamol and 
lornoxicam effectively decreased the pain scores. The 
patients were satisfied with the three postoperative pain 
management regimens.10 
                 Ilias et al (1996) studied pain relief after 
hysterectomy in an observer blind randomized trial of 
lornoxicam versus tramadol. The study included 78 female 
patients aged 20-65 years with moderate to intolerable 
postoperative pain following hysterectomy. After surgery 
lornoxicam was given as intravenous injection in a dose of 
4mg and 8mg while tramadol was given in a dose of 50mg. 
Patients who received lornoxicam 8mg had a significantly 
longer time to first remedication than placebo recipients 
and tended to have a greater reduction in pain intensity and 
a longer time to withdrawal due to non-response than 
tramadol and placebo patients. Lornoxicam was well 
tolerated at both doses and was associated with a longer 
incidence of adverse effects than tramadol. Thus, 
intravenous lornoxicam at a dose of 8mg was superior to 
placebo and at least as effective as intravenous tramadol 
50mg in relieving moderate to intolerable 
posthysterectomy pain. Furthermore, lornoxicam seemed 
to possess a more favourable tolerability profile than 
tramadol.11 
Herrmann et al conducted a five-day double-
blind, randomised study in which the efficacy and safety of 
oral lornoxicam as early treatment of acute sciatica/lumbo-
sciatica was compared with placebo and diclofenac. The 
study concluded that the analgesic efficacy of lornoxicam 
is superior to placebo and similar to diclofenac in acute 
sciatica/lumbo-sciatica.12 
Rosenow et al conducted an observer-blind, 
placebo-controlled, multiple-dose study to determine the 
efficacy of lornoxicam in postoperative pain on 80 patients 
with moderate to severe pain after laminectomy, who were 
randomised to receive lornoxicam 4 or 8mg intravenously, 
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pethidine 50mg intravenously or isotonic distilled water 
(placebo) at their first request for analgesia. The study 
concluded that lornoxicam 8mg intravenously was as 
effective as pethidine 50mg intravenously in relieving 
moderate to severe post-laminectomy pain, and had few 
adverse events.13  
Daglar et al conducted a studyto compare the 
efficacy and tolerability of lornoxicam and diclofenac 
sodium in pain management after coronary artery bypass 
grafting (CABG). The study concluded that the efficacy of 
lornoxicam and diclofenac were similar in postoperative 
pain management and both study drugs were well 
tolerated.14 
Mentes et al conducted arandomized and 
prospective study to compare the analgesic effects of 
lornoxicam and tramadol in patients after inguinal hernia 
repair and concluded that both lornoxicam and tramadol 
provided rapid and effective analgesia and were well 
tolerated.15 
              Staunstrup et al (1999) studied the efficacy and 
tolerability of lornoxicam versus tramadol for 
postoperative pain relief following arthroscopic 
reconstruction of the anterior cruciate ligament. This 
randomized double blind study consisted of 76 patients 
with moderate to unbearable pain. Patients receiving a 
single dose of 16mg intramuscular lornoxicam experienced 
significantly greater pain relief than patients receiving 
100mg intramuscular tramadol over the following 8 hours. 
Lornoxicam had greater analgesic efficacy than tramadol 
in patients with moderate base line pain but was of 
equivalent efficacy in those with severe or unbearable base 
line pain. Fewer patients in the lornoxicam group required 
rescue medication (58% versus 77% respectively). The 
authors concluded that intramuscular lornoxicam offers a 
useful alternative to tramadol for the treatment of moderate 
to severe postoperative pain.16 
Lornoxicam has also been compared to other 
NSAIDs in addition to its comparison to opioid analgesics. 
Papadima et al (2006) compared lornoxicam with 
parecoxib in the treatment of postoperative pain after 
laparoscopic cholecystectomy in a prospective randomized 
placebo controlled trial. The authors concluded that 
parecoxib 40mg intravenous and lornoxicam 8mg 
intravenous were equianalgesic and both were more 
efficacious than placebo for the management of pain after 
laparoscopic cholecystectomy.17 
Arslan et al (2006) studied the postoperative 
analgesic effect of lornoxicam after thyroidectomy in a 
placebo controlled randomized trial. They used a dose of 
8mg intravenous at the end of surgery followed by 8mg 
twice a day for 24 hours postoperatively. Authors opined 
that pain scores alongwith incidence of nausea and 
vomiting decrease with the use of lornoxicam.18 
Sapolya et al (2007) investigated the analgesic 
effects of lornoxicam after total abdominal hysterectomy 
in a randomixed placebo controlled double blond study. 
Fifty patients were randomized to receive either oral 
placebo or lornoxicam 8mg one hour before surgery. All 
patients received patient controlled analgesia with 
tramadol. The authors concluded that a single oral dose of 
lornoxicam given preoperatively enhanced the analgesic 
effect of tramadol, decreasing tramadol consumption and 
side effect and shortened the length of hospitalization.19  
Inan et al (2007) studied efficacy of lornoxicam 
as postoperative analgesic after total knee replacement 
surgery. In this double blind randomized placebo 
controlled study, the effect of lornoxicam (16mg 
intravenously 15 minutes before surgery folloed by 8mg 
postoperatively at 12th and 24th hours) on morphine 
consumption was investigated. It was observed that 
lornoxicam administration decreased morphine 
consumption in postoperative period significantly and 
there were fewer side effects.20  
Erdogan et al studied, the effect of lornoxicam on 
postoperative pain after myomectomy and observed that 
single dose intravenous lornoxicam (8mg) was safe and 
effective treatment option for relief of post myomectomy 
pain. It reduced the consumption of morphine 
significantly.21  
There are only a few studies available in literature 
comparing the analgesic effect of lornoxicam and 
diclofenac. Behdir et al (2005) studied the comparison of 
the effects of lornoxicam versus diclofenac in pain 
management after cardiac surgery in a single blind 
randomized study. The study included 40 adult patients 
who were randomly assigned to either receive lornoxicam 
8mg intramuscularly 8 hourly or diclofenac 75mg 
intramuscular 12 hourly for 48 hours. Pethidine 1mg/Kg 
intramuscular was given for additional analgesia 
postoperatively when needed. No significant group 
difference in mean pain relief scores was found at any 
point in both groups.22  
Sener et al (2008) in a prospective, randomized, 
placebo controlled double blind study compared the 
efficacy of lornoxicam with diclofenac, ketoprofen and 
dipyrone for relief of acute postoperative pain in patient 
undergoing septoplasty. Patients were divided into five 
groups depending upon the drug used. The drugs were 
used intramuscularly. They used lornoxicam (8 twice 
daily), diclofenac (75mg twice daily), ketoprofen (100mg 
twice daily), dipyrone (1gm thrice daily) and placebo 
(twice daily). Intramuscular pethidine 1mgKg-1 was used 
as resuce analgesia. Pethidine requirement was found to be 
significantly higher in the placebo group. However, there 
was no significant difference among the remaining four 
groups.23  
In comparative studies in healthy volunteers, 
lornoxicam 16 mg/day induced significantly less 
endoscopically verified gastroduodenal injury than 
naproxen 1000 mg/day.24 Lornoxicam 8 mg/day tended to 
cause less faecal blood loss than indomethacin 100 
mg/day.25 There is  another comparative study, reporting 
efficaciousness  of loroxicam in acute renal colic 
treatment.26 
The above reviewed studies reveal that non-
steriodal anti-inflammatory drugs have differing 
pharmacology, varying dosing schedule, side effect profile 
and duration of analgesia. Although lornoxicam is more 
than a decade old NSAID but is has been recently 
introduced in India. A small number of preliminary 
placebo-controlled and other comparative clinical studies 
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have shown that lornoxicam provides effective analgesia 
following surgery.  
TOLERABILITY
 
Lornoxicam has a tolerability profile 
characteristic of NSAIDs, with gastrointestinal 
disturbances (pain, dyspepsia, nausea, vomiting) being the 
most prominent events. In comparative clinical trials, the 
tolerability of oral lornoxicam appeared to be similar to 
that of diclofenac and better than that of indomethacin in 
patients with arthritic conditions or chronic low back pain. 
As would be expected, parenterally administered 
lornoxicam tended to be better tolerated than parenteral 
opioid analgesics in patients with postoperative pain.27 
CONCLUSIONS 
 The drug has been found to be safe in elderly patients, 
patients with impaired renal function and patients with 
impaired hepatic functions. The data from clinical studies 
indicate that lornoxicam has an better analgesic effects and 
antiinflammatory properties as compare to other NSAIDs  
in the treatment of acute, moderate to severe pain  but still 
there is a need to  require confirmation in further 
comparative studies.  
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